JP2025500430A5 - - Google Patents
Info
- Publication number
- JP2025500430A5 JP2025500430A5 JP2024537994A JP2024537994A JP2025500430A5 JP 2025500430 A5 JP2025500430 A5 JP 2025500430A5 JP 2024537994 A JP2024537994 A JP 2024537994A JP 2024537994 A JP2024537994 A JP 2024537994A JP 2025500430 A5 JP2025500430 A5 JP 2025500430A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- nhc
- compound according
- nhnh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292910P | 2021-12-22 | 2021-12-22 | |
| US63/292,910 | 2021-12-22 | ||
| US202263313040P | 2022-02-23 | 2022-02-23 | |
| US63/313,040 | 2022-02-23 | ||
| US202263322528P | 2022-03-22 | 2022-03-22 | |
| US63/322,528 | 2022-03-22 | ||
| PCT/US2022/082136 WO2023122662A1 (en) | 2021-12-22 | 2022-12-21 | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500430A JP2025500430A (ja) | 2025-01-09 |
| JP2025500430A5 true JP2025500430A5 (https=) | 2026-01-05 |
Family
ID=85278679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537994A Pending JP2025500430A (ja) | 2021-12-22 | 2022-12-21 | Ｋ－ＲＡＳ ＧＴＰａｓｅのＧ１２Ｓ、Ｇ１２Ｄ、及び／又はＧ１２Ｅ変異体の共有結合阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250059187A1 (https=) |
| EP (1) | EP4452416A1 (https=) |
| JP (1) | JP2025500430A (https=) |
| AU (1) | AU2022421224A1 (https=) |
| CA (1) | CA3240772A1 (https=) |
| IL (1) | IL313428A (https=) |
| MX (1) | MX2024007780A (https=) |
| TW (1) | TW202340202A (https=) |
| WO (1) | WO2023122662A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| CN119790059A (zh) * | 2022-08-30 | 2025-04-08 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025096984A1 (en) * | 2023-11-02 | 2025-05-08 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| AU2024374420A1 (en) * | 2023-11-02 | 2026-04-16 | Kumquat Biosciences Inc. | Degraders and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025212580A1 (en) * | 2024-04-01 | 2025-10-09 | Xdc Precision Therapeutics Llc | Antibody-kras binder conjugates, pharmaceutical compositions, and therapeutic applications |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| PT970957E (pt) * | 1998-06-12 | 2002-02-28 | Hoffmann La Roche | Derivados de diaza-espiro¬3,5|nonamo |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| WO2008033447A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| PL2748166T3 (pl) * | 2011-08-23 | 2019-05-31 | Asana Biosciences Llc | Związki pirimido-pirydazynonowe oraz ich zastosowanie |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| CN108473498B (zh) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| US10759750B2 (en) * | 2016-04-29 | 2020-09-01 | Temple University—Of the Commonwealth System of Higher Education | Beta lactams as modulators of glutamate uptake and methods for use thereof |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| EP3612526A2 (en) * | 2017-04-20 | 2020-02-26 | The Regents of the University of California | K-ras modulators |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US10961209B2 (en) * | 2017-08-10 | 2021-03-30 | Novomer, Inc. | Processes for producing beta-lactone and beta-lactone derivatives with heterogenous catalysts |
| US12098138B2 (en) * | 2018-05-25 | 2024-09-24 | The Board Of Regents Of The University Of Texas System | Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases |
| PE20260440A1 (es) | 2018-11-09 | 2026-02-19 | Hoffmann La Roche | Compuestos de anillo fusionado |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| GB201910168D0 (en) * | 2019-07-16 | 2019-08-28 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| CN114269735B (zh) | 2019-08-26 | 2024-02-23 | 南京创济生物医药有限公司 | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 |
| PT3886991T (pt) | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
-
2022
- 2022-12-21 TW TW111149250A patent/TW202340202A/zh unknown
- 2022-12-21 US US18/720,571 patent/US20250059187A1/en active Pending
- 2022-12-21 CA CA3240772A patent/CA3240772A1/en active Pending
- 2022-12-21 WO PCT/US2022/082136 patent/WO2023122662A1/en not_active Ceased
- 2022-12-21 EP EP22859496.6A patent/EP4452416A1/en active Pending
- 2022-12-21 JP JP2024537994A patent/JP2025500430A/ja active Pending
- 2022-12-21 IL IL313428A patent/IL313428A/en unknown
- 2022-12-21 MX MX2024007780A patent/MX2024007780A/es unknown
- 2022-12-21 AU AU2022421224A patent/AU2022421224A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500430A5 (https=) | ||
| JP5030229B2 (ja) | プロテインキナーゼのインヒビターとして有用なピラゾロ［１，５−ａ］ピリミジン | |
| ES2287107T3 (es) | Compuestos de 3,4-dihidro-1h-pirimido-4,-dipirimidin -2-ona 1,5-disustituidos y su uso en el tratamiento de enfermedades mediadas por csbp/p38 cinasa. | |
| CN112592334B (zh) | 嘧啶衍生物作为激酶抑制剂 | |
| AU2007325576B2 (en) | Compositions of Chk1 inhibitors | |
| US12428416B2 (en) | ERK inhibitors and uses thereof | |
| RU2020118594A (ru) | Противораковые агенты | |
| AU2014331628B2 (en) | Inhibitors of ERK and methods of use | |
| US9649309B2 (en) | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | |
| JP2008519059A5 (https=) | ||
| JP2006507254A5 (https=) | ||
| JP2004509118A5 (https=) | ||
| JP2019536763A (ja) | インターロイキン−２誘導性ｔ細胞キナーゼを調節する化合物及び方法 | |
| JP2020536847A (ja) | プログラマブルなポリマー薬物 | |
| JP5965923B2 (ja) | プロテインキナーゼ阻害剤としてのリン含有化合物 | |
| JP2006511490A5 (https=) | ||
| JPH07110852B2 (ja) | 二芳香族置換抗ａｉｄｓ化合物 | |
| JP2002523511A5 (https=) | ||
| CN110141570A (zh) | 药物化合物 | |
| KR20010072392A (ko) | Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드 | |
| IL324876A (en) | Parp1 inhibitors and uses thereof | |
| KR20050105190A (ko) | Ｈｉｖ를 저해하는 1,2,4-트리아진 | |
| JP2016522232A5 (https=) | ||
| AU2023213731A1 (en) | Parp1 inhibitors and uses thereof | |
| JP2008504353A (ja) | ゲムシタビン誘導体ナノ粒子 |